top of page

Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. 

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery. 
Biofit Europe 2020
TechTour Europe Future 2022 Award Winner

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022

EIT Health Catapult Biotech pitching competition Finalist StemSight

Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023


About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.

Latest news


Laura Koivusalo on stage at HLTH Europe

The legendary HLTH event lands in Amsterdam on the 17th-20th of June! Our CEO Laura is speaking on the Startup Stage on the final day of the event in the EIT Health Catapult panel.


StemSight is presenting at Bio€quity 2024

On May 12 to May 15, our CEO Laura Koivusalo will be attending the Bio€quity biotech investor meeting in San Sebastian, Spain. Laura will give a presentation about StemSight and our latest achievements on May 14 at 11:00 as part of the Cell and Gene Therapy Track. Meetings with Laura can be requested through the event partnering system!


StemSight moves to second phase of EIC Accelerator

As an innovative technology company focused on creating lasting benefits to the European health ecosystem, StemSight is a prime candidate for EU's EIC Accelerator funding. This highly competitive funding scheme requires two application phases, and a final interview. We are glad to announce that we have received very positive evaluation from the four independent evaluators on our first phase application and are eager to move to the next step!


StemSight attends OBN's BioSeed in London June 11

StemSight is happy to be pitching at the Summer edition of BioSeed, organized in Canary Wharf on the 11th of June. Our CEO Laura is available for meetings to hear the latest updates of our Seed financing round. If you're around, don't miss your chance!


StemSight wins Dragon's Den competition at Finnish Biotechs & Investors meeting

Tesi, Innovestor and HealthCap co-organized the first Finnish Biotechs and Investors meeting, where StemSight participated in the Dragon's Den -type pitching competition. StemSight was selected as the winner from the pitching companies!


Laura Koivusalo speaks at Advanced Therapies in London

Our CEO Laura attends the Advanced Therapies event in London on March 19-20. Laura joins other prominent Cell and Gene Therapy leaders in an expert panel on Autologous vs. Allogeneic approaches in cell therapy.

Investor presentation

We are in discussions with international biotech and life science investors and corporates to get our life-changing products to first patients.



Want to know more?

Interested to join our next investment round?

Want to hear about our latest developments?

Just thought of someone we absolutely need to meet?


Send us a message!

Supported by:

Voima Ventures
Stephen Industries
Business Finland
Spark Finland
Avoihoidon Tutkimussäätiö

Co-funded by:

European Union
Leverage from the EU 2014-2020
bottom of page